Eight patients with aggressive non-Hodgkin's lymphoma treated with Kite Pharma Inc.'s cancer drug lead candidate were in complete remission and four others in partial remission, the company said Monday.. Shares surged 29% to $28.70 in recent after-hours trading, well above their $17 debut but shy of the 52-week high set on June 24, shortly after the company's initial public offering. . The...
  